
    
      CONSORTIUM-IO is a first-in-human multicenter, open-label study, where it's main objectives
      will evaluate:

        -  Safety and tolerability of VE800 in combination with Nivolumab

        -  Efficacy as measured by a total of overall response rate.

      The study will enroll approximately 111 patients with melanoma, patients with
      gastric/gastroesophageal junction (GEJ) adenocarcinoma, and patients with
      microsatellite-stable (MSS) colorectal cancer (CRC).

      Nivolumab is an already approved by the FDA (the U.S. Food and Drug Administration), however,
      it is not approved for the study cancer indications. VE800 is the investigational product and
      alive VE800 bacterial consortium were designed to elicit an immune response.
    
  